Moxy Drug-Coated Balloon: Completed Phase II enrollment

Bard's Lutonix technology center completed enrollment of 476 patients with diseased femoropopliteal leg arteries in the single-blind, international, pivotal Phase II LEVANT 2 trial evaluating its Luto...